Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
Kymera Therapeutics reported Q2 2026 financial results highlighting rapid enrollment completion of their KT-621 Phase 2b trial in atopic dermatitis ahead of schedule, with topline data expected by year-end 2026. The company plans to initiate Phase 3 trials in mid-2027 and reported ongoing progress in multiple clinical programs addressing immunologi…